^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    BIOMARKER:

    CD38 expression

    i
    Entrez ID:
    952
    Related biomarkers:
    Expression
    Others
    Apply
    XmAb18968 (CD3-CD38) in Relapsed or Refractory Acute Leukemia and T Cell Lymphoblastic Leukemia (PRO00041908) (NCT05038644)
    Phase 1
    Ehab L Atallah
    Recruiting
    Last update posted :
    04/03/2024
    Initiation :
    02/02/2022
    Primary completion :
    10/01/2025
    Completion :
    10/01/2026
    CD38
    |
    CD38 expression
    |
    XmAb968
    SG301 Safety Study in Subjects With Relapsed or Refractory Multiple Myeloma and Other Hematological Malignancies (NCT04684108)
    Phase 1
    Hangzhou Sumgen Biotech Co., Ltd.
    Active, not recruiting
    Last update posted :
    03/28/2024
    Initiation :
    11/04/2021
    Primary completion :
    06/30/2024
    Completion :
    12/31/2024
    CD38
    |
    CD38 expression
    |
    SG301 IV
    Study of Elranatamab for Relapsed or Refractory Myeloma in Patients Previously Exposed to Three-drug Classes (NCT06282978)
    Phase 2
    PETHEMA Foundation
    Recruiting
    Last update posted :
    03/06/2024
    Initiation :
    11/23/2023
    Primary completion :
    05/01/2025
    Completion :
    12/01/2029
    KIT • CD19 • CD38 • PTPRC • NCAM1 • CD27 • CD81
    |
    CD38 expression • CD19 expression • NCAM1 expression • CD27 expression • CD5 overexpression • NCAM1 overexpression
    |
    Elrexfio (elranatamab-bcmm)
    FT538 in Combination With Daratumumab in AML Acute Myeloid Leukemia (NCT04714372)
    Phase 1
    Masonic Cancer Center, University of Minnesota
    Active, not recruiting
    Last update posted :
    01/10/2024
    Initiation :
    11/03/2021
    Primary completion :
    01/09/2024
    Completion :
    12/15/2025
    FLT3 • IDH1 • IDH2 • CD38
    |
    CD38 expression
    |
    cyclophosphamide • Darzalex (daratumumab) • fludarabine IV • Darzalex Faspro (daratumumab and hyaluronidase-fihj) • FT538 • cyclophosphamide intravenous
    Genomic and Phenotypic Determinants of Resistance to Immunotherapies in Multiple Myeloma (NCT03848676)
    Phase N/A
    University of Turin, Italy
    Active, not recruiting
    Last update posted :
    09/21/2023
    Initiation :
    07/01/2018
    Primary completion :
    06/01/2024
    Completion :
    07/01/2024
    CD8 • IL6 • CD38 • CRBN • DKK1 • CD4 • CD55 • CD59
    |
    CD38 expression • CRBN mutation
    CART-38 in Adult AML and MM Patients (NCT05442580)
    Phase 1
    University of Pennsylvania
    Recruiting
    Last update posted :
    06/22/2023
    Initiation :
    05/30/2023
    Primary completion :
    05/01/2041
    Completion :
    05/01/2041
    CD38 • CD34
    |
    CD38 expression
    |
    cyclophosphamide • fludarabine IV • CART-38
    Daratumumab-containing Induction Effects on Stem Cells Mobilization, colLection and Engraftment in Newly Diagnosed Multiple MyelomA Patients. (DILEMMA) (NCT05835726)
    Phase N/A
    Fondazione Policlinico Universitario Agostino G...
    Recruiting
    Last update posted :
    05/01/2023
    Initiation :
    01/01/2022
    Primary completion :
    12/31/2023
    Completion :
    04/30/2024
    CD38 • CD34
    |
    CD38 expression
    |
    bortezomib • Darzalex (daratumumab)
    Study to Assess Allogeneic Anti-CD38 A2 Dimeric Antigen Receptor T Cells in Relapsed or Refractory Multiple Myeloma (NCT05007418)
    Phase 1b
    Sorrento Therapeutics, Inc.
    Recruiting
    Last update posted :
    01/16/2023
    Initiation :
    10/01/2022
    Primary completion :
    12/01/2025
    Completion :
    02/01/2026
    CD38
    |
    CD38 expression
    |
    STI-1492
    Evaluation of the Safety and Efficacy of the Association of Ibrutinib and Daratumumab in Relapsed/Refractory Chronic Lymphocytic Leukemia With p53 Dysfunction (IDA53) (NCT03734198)
    Phase 2
    French Innovative Leukemia Organisation
    Active, not recruiting
    Last update posted :
    06/28/2022
    Initiation :
    12/19/2018
    Primary completion :
    06/01/2024
    Completion :
    06/01/2026
    TP53 • CD38
    |
    TP53 mutation • CD38 expression
    |
    Imbruvica (ibrutinib) • Darzalex (daratumumab)
    Chemotherapy Followed by Allogeneic Stem Cell Transplantation for Hematologic Malignancies (NCT00741455)
    Phase N/A
    Dartmouth-Hitchcock Medical Center
    Completed
    Last update posted :
    11/23/2020
    Initiation :
    06/01/2004
    Primary completion :
    05/01/2020
    Completion :
    05/01/2020
    CD38
    |
    CD38 expression
    |
    cyclophosphamide • fludarabine IV • cyclosporine • cyclophosphamide intravenous
    Personalized Targeted Preparative Regimen Before T-depleted Allogeneic HSCT in Children With Chemoresistent Acute Leukemias (NCT04000698)
    Phase 3
    Federal Research Institute of Pediatric Hematol...
    Recruiting
    Last update posted :
    11/20/2020
    Initiation :
    10/15/2019
    Primary completion :
    07/01/2022
    Completion :
    12/01/2022
    BCL2 • CXCR4 • CD38
    |
    CD38 expression • BCL2 expression
    |
    Venclexta (venetoclax) • cytarabine • Actemra IV (tocilizumab) • Grafapex (treosulfan)
    Imprime PGG, Alemtuzumab, and Rituximab in Treating Patients With High Risk Chronic Lymphocytic Leukemia (NCT01269385)
    Phase 1/2
    Mayo Clinic
    Completed
    Last update posted :
    06/23/2020
    Initiation :
    01/01/2011
    Primary completion :
    06/01/2014
    Completion :
    06/01/2015
    CD20 • CCND1 • IGH • CD38 • CD5 • FCER2
    |
    CD38 expression • CD20 expression
    |
    Rituxan (rituximab) • Campath (alemtuzumab) • Imprime PGG (odetiglucan)
    Rituximab, Alemtuzumab, and GM-CSF As First-Line Therapy in Treating Patients With Early-Stage Chronic Lymphocytic Leukemia (NCT00562328)
    Phase 2
    Mayo Clinic
    Completed
    Last update posted :
    04/08/2020
    Initiation :
    01/01/2008
    Primary completion :
    02/05/2010
    Completion :
    12/18/2014
    CD20 • CCND1 • CD38 • CD5 • FCER2
    |
    CD19 positive • CD38 expression • CD20 expression • CD5 positive
    |
    Rituxan (rituximab) • Campath (alemtuzumab) • Leukine (sargramostim)
    Rituximab Versus Observation as Maintenance Therapy in Chronic Lymphocytic Leukemia (Chronic Lymphocytic Leukemia) (NCT01118234)
    Phase 3
    Arbeitsgemeinschaft medikamentoese Tumortherapie
    Completed
    Last update posted :
    01/09/2020
    Initiation :
    12/01/2009
    Primary completion :
    02/01/2018
    Completion :
    07/01/2019
    CD38
    |
    Chr del(11q) • CD38 expression • TS 12
    |
    Rituxan (rituximab)
    A Phase I/II Study to Assess the Safety and Tolerability of APO866 for the Treatment of Refractory B-CLL (NCT00435084)
    Phase 1/2
    Onxeo
    Completed
    Last update posted :
    09/23/2015
    Initiation :
    02/01/2007
    Primary completion :
    02/01/2008
    Completion :
    04/01/2009
    BCL2 • CD38 • CD5 • FCER2
    |
    CD38 expression
    |
    daporinad (APO866)
    Lenalidomide in Treating Patients With High-Risk Chronic Lymphocytic Leukemia (NCT01271283)
    Phase 2
    National Cancer Institute (NCI)
    Withdrawn
    Last update posted :
    06/04/2015
    Initiation :
    12/01/2010
    Primary completion :
    08/01/2011
    Completion :
    08/01/2011
    IGH
    |
    Chr del(11q) • CD38 expression • IGH mutation
    |
    lenalidomide